TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03335033

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Contrast-enhanced ultrasound
Description: Subjects will receive a low mechanical index (0.17-0.20) imaging during ultrasound contrast agent intravenous infusion. Real-time cine-loop including longitudinal and transverse images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the carotid artery will be acquired and digitally stored for offline analysis. Also use of a 3D ultrasound transducer to evaluate the feasibility of using US images with contrast to assess the residual diameter of the diseased vessel. Specifically, two 3D acquisitions of each lesion would be obtained after contrast has been injected.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Contrast-enhanced ultrasound
Description: Subjects will receive a low mechanical index (0.17-0.20) imaging during ultrasound contrast agent intravenous infusion. Real-time cine-loop including longitudinal and transverse images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the carotid artery will be acquired and digitally stored for offline analysis. Also use of a 3D ultrasound transducer to evaluate the feasibility of using US images with contrast to assess the residual diameter of the diseased vessel. Specifically, two 3D acquisitions of each lesion would be obtained after contrast has been injected.
Study: NCT01870973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root canal treatment, anesthesia, pain medications, and antibiotic
Description: Root canal treatment is the intervention (no initial treatment versus initial treatment). We are not studying a drug or device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no root canal treatment, anesthesia, pain medications, and antibiotic
Study: NCT02671799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenTouch System Implant
Description: The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is intended for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable mainly to annular dilatation with or without papillary muscle displacement. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is used to reshape the base of the heart to bring the mitral valve leaflets into better coaptation. By doing so, it brings the mitral valve leaflets closer, allowing proper closure of the valve, and reducing or eliminating MR. There is provision of support to the ventricular myocardium below the annulus as well as the annulus, so the VenTouch System may allow long-term ventricular remodeling with positive impact on the functionality of the mitral valve.
Study: NCT02623933

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI assisted focal boost with HDR monotherapy
Description: Prior to brachytherapy treatment, a multiparametric MRI will be obtained for identification of the dominant intraprostatic lesion (DIL) and fused with the preplanning transrectal ultrasound. A total of 19 Gy will be prescribed to the prostate, organ at risk limits will be observed and up to 22.5 Gy can be delivered to the DIL
Study: NCT03335033

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shear Wave Elastography
Description: Shear wave elastography will be performed with the General Electric Logiq E9 scanner acquiring images of each plaque in the longitudinal and transverse imaging planes. In each plane 10 measurements will be made and the in-phase/quadrature (IQ) data will be saved for further analysis. The plaque area in the imaging plane will be user-defined to extract the wave velocity values for a ROI analysis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shear Wave Elastography
Description: Shear wave elastography will be performed with the General Electric Logiq E9 scanner acquiring images of each plaque in the longitudinal and transverse imaging planes. In each plane 10 measurements will be made and the in-phase/quadrature (IQ) data will be saved for further analysis. The plaque area in the imaging plane will be user-defined to extract the wave velocity values for a ROI analysis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Examination
Description: A standard carotid US examination using Duplex imaging will performed using a linear array transducer to obtain longitudinal and transverse images. All ultrasound measurements will be made by a trained registered vascular technologist. Severity of stenosis of the plaque will be measured based on established protocol and guidelines.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Examination
Description: A standard carotid US examination using Duplex imaging will performed using a linear array transducer to obtain longitudinal and transverse images. All ultrasound measurements will be made by a trained registered vascular technologist. Severity of stenosis of the plaque will be measured based on established protocol and guidelines.
Study: NCT01559298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin (80 mg/d) + clopidogrel (75 mg/d)
Description: Aspirin (80 mg/d) + clopidogrel (75 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months. Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months. Patients will be followed either by phone contact or clinical visits at 1- and 12-month follow-up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin (80 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
Study: NCT03516448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gan Fu Le Tablets
Description: 6 Tablets，tid,po

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gan Fu Le Tablets
Description: 6 Tablets，tid,po

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tyroserleutide for injection
Description: 6mg/d, 5days,ivgtt

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0mg/d, 5days,ivgtt
Study: NCT02429882

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brodalumab 210 mg
Description: 210 mg brodalumab will be administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously
Study: NCT01392560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: Oral once daily
Study: NCT03809481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danaparoid Sodium
Description: inhibits thrombin generation by indirect anti-Xa inhibition and direct inhibition of factor IX activation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Argatroban
Description: Synthetic direct thrombin inhibitor
Study: NCT03071692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877
Description: 0.2mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: K-877 matching placebo tablet
Study: NCT00649194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium Delayed-Release Tablets 20 mg
Description: 20mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aciphex® Tablets 20 mg
Description: 20mg, single dose fed
Study: NCT00088231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate (Gleevec)
Description: 600 mg by mouth every day (for AML, CML-BP) for a 28 day cycle.~400 mg by mouth every day (for AMM) for a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK 787 (vatalanib)
Description: For 1 week prior to receipt of the study combination regimen, all patients will receive single agent PTK 787 at the dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels.~Starting dose: 250 mg by mouth every day for a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK 787 (vatalanib)
Description: For 1 week prior to receipt of the study combination regimen, all patients will receive single agent PTK 787 at the dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels.~Starting dose: 250 mg by mouth every day for a 28 day cycle.
Study: NCT03651089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP16
Description: subcutaneous injection of experimental anti-inflammatory drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP16
Description: subcutaneous injection of experimental anti-inflammatory drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP16
Description: subcutaneous injection of experimental anti-inflammatory drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: subcutaneous injection of sterile saline
Study: NCT00682734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Description: metoclopramide 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Description: metoclopramide 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: metoclopramide 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine 25mg
Description: Diphenhydramine 25mg, administered as an intravenous drip over 20 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 25mg
Description: Diphenhydramine 25mg, administered as an intravenous drip over 20 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 25mg
Description: Diphenhydramine 25mg, administered as an intravenous drip over 20 minutes
Study: NCT04100005

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study.
Study: NCT03715933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-109
Description: Tetravalent DR5 Agonist Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-109
Description: Tetravalent DR5 Agonist Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-109
Description: Tetravalent DR5 Agonist Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-109
Description: Tetravalent DR5 Agonist Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-109
Description: Tetravalent DR5 Agonist Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-109
Description: Tetravalent DR5 Agonist Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-109
Description: Tetravalent DR5 Agonist Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-109
Description: Tetravalent DR5 Agonist Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-109
Description: Tetravalent DR5 Agonist Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-109
Description: Tetravalent DR5 Agonist Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-109
Description: Tetravalent DR5 Agonist Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Chemotherapy
Study: NCT03753061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspiration Catheter
Description: Patients will be treated for mechanical recanalization with Aspiration Catheter within 8 hours after stroke onset plus standard medical management.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solitaire FR
Description: Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
Study: NCT01414387

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid filter
Description: Patients randomized to this group will receive filter devices to prevent cerebral embolization during carotid stenting, assessed by intraoperative transcranial Doppler and postoperative cerebral DW-MRI.~The filter used for this trial is the RX accunet embolic protection system manufactured by abbott.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid reversal of flow
Description: On the flow reversal arm two type of devices will be used. The first is the Gore flow reversal system, manufactured by LW Gore and the second device is the IVANTEC MoMa Ultra Embolic protection device, manufatured by IVANTEC.
Study: NCT03813940

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine,135μg/0.5ml
Description: HPV vaccine (135μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine,270μg/1.0ml
Description: HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
Study: NCT04588350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-SEP autotransfusion system
Description: Intraoperative recovery and washing of the processed blood by i-SEP autotransfusion system in surgeries where a bleeding is expected
Study: NCT03734627

Intervention type: DRUG
Intervention: Octreotide Acetate
Description: 50mcg octreotide acetate by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge

Intervention type: DRUG
Intervention: Octreotide Acetate
Description: 50mcg octreotide acetate by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
Study: NCT02056184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Study: NCT01797887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Lifestyle Counseling
Description: Diet and Lifestyle Counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Lifestyle Counseling
Description: Diet and Lifestyle Counseling
Study: NCT02069041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Description: Administered IV.
Study: NCT03476889

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula
Description: Infants are randomized to one of two infant formulas from \<14 days of age to 17 weeks of age.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula
Description: Infants are randomized to one of two infant formulas from \<14 days of age to 17 weeks of age.
Study: NCT04122313

Intervention type: OTHER
Intervention: Evaluation of Dupuytren's Disease Treatment
Description: There are no study interventions. The study interaction will be asking the patients to complete an additional outcome questionnaire and allow a medical record review.
Study: NCT01707966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orteronel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00230659

Intervention type: OTHER
Intervention: Blood sample to be taken.
Description: Blood sample to be taken.

Intervention type: OTHER
Intervention: Blood sample to be taken.
Description: Blood sample to be taken.
Study: NCT04002115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine to be administered pre-stem cell transplant infusion (Day 0) once a day for 5 days total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered once a day for 4 days as part of the transplant conditioning regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan will be administered once a day for 2 days as part of the transplant conditioning regimen.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: TBI will be administered at a dose of 200cGys on Day -1 prior to transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given once a day for 2 days after the transplant infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: G-CSF will be administered to subjects starting on Day +5 and will continue as clinically indicated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will be administered to subjects starting on Day +5 and will continue as clinically indicated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellcept
Description: Mycophenolate Mofetil will be administered to subjects starting on Day +5 and will continue as clinically indicated
Study: NCT00463047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone
Description: Patients will be randomly assigned in a 1:1 ratio either to titrate immediate-release oxycodone first and to titrate FBT second, or to titrate FBT first and immediate-release oxycodone second, followed by 2 double-blind crossover treatment periods (in randomized order). For the double-blind treatment period of the study involving FBT administration, a patient is randomly assigned to receive FBT at the 200, 400, 600, or 800 mcg strength found to be successful during open-label titration. For the double-blind treatment period of the study to which a patient is randomly assigned to receive immediate-release oxycodone, the patient will receive immediate-release oxycodone at the strength (15, 30, 45, or 60 mg) found to be successful during open-label titration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone
Description: Patients will be randomly assigned in a 1:1 ratio either to titrate immediate-release oxycodone first and to titrate FBT second, or to titrate FBT first and immediate-release oxycodone second, followed by 2 double-blind crossover treatment periods (in randomized order). For the double-blind treatment period of the study involving FBT administration, a patient is randomly assigned to receive FBT at the 200, 400, 600, or 800 mcg strength found to be successful during open-label titration. For the double-blind treatment period of the study to which a patient is randomly assigned to receive immediate-release oxycodone, the patient will receive immediate-release oxycodone at the strength (15, 30, 45, or 60 mg) found to be successful during open-label titration.
Study: NCT00140244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-metHuLeptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01709682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Arrhythmia Agents (propafenone, flecainide, and/or sotalol, or amiodarone)
Description: propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: re-ablation procedure
Description: Reisolation of the PVs was performed by identifying the breakthrough site on the mapping catheter (NaviStar ThermoCool, Biosense-Webster Inc., Diamond Bar, CA). RF energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of ablation was complete PVI; this was confirmed when Lasso catheter mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILR implantation
Description: The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a tool that allows each patient to store the ECG through the implanted device during symptoms; data were collected in order to analyze heart rhythm during symptomatic events.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILR implantation
Description: The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a tool that allows each patient to store the ECG through the implanted device during symptoms; data were collected in order to analyze heart rhythm during symptomatic events.
Study: NCT03616873

Intervention type: OTHER
Intervention: Early Mobilization
Description: The EM program consists of a progression of functional activities from level of function (LOF) 0 (lowest mobility) to 5 (highest mobility). Each LOF has 3 primary activities designed to promote the patient to the next level. The nurse will begin with mobility activities based on the LOF that matches the patient's current status. The nurse and clinical partner will attempt and/or complete each LOF activity once per shift.